Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies

Video content above is prompted by the following:

• Does your enthusiasm about recommending adjuvant anti–PD-1 differ based on the following variables?
  • Receipt of NAC vs not
  • Nodal involvement on original imaging and/or at surgery in final path
  • Positive surgical margin
  • Variant histologies (squamous, plasmacytoid, micropapillary, sarcomatoid, etc)
  • PD-L1 expression
  • What patient specific factors influence your decision to observe/monitor, rather than treat, your patients with >pT2 or ≥ypT2 stage and/or pN+ (eg, prior autoimmune disease, frailty, age)?
    • MIBC vs not